Human neutralizing monoclonal antibodies to respiratory syncytial virus
US7364737B2 · kind B2 · utility
13Cited by
8References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2004 |
| Grant date | Apr 29, 2008 |
| Priority date | — |
| Expiry date | Sep 8, 2024 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/867
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.